Glaxo and Sanofi intend to supply the UK with 60 million doses of their vaccine if the investigation is successful
The British Pharmacist GlaxoSmithKline and the french Sanofi, partners in the development of the vaccine, seek an agreement of 550 million euros to supply the UK in case your investigation is successful.
This was confirmed by sources close to this matter to Bloomberg, who explained that these companies intend to supply the islands with 60 million doses of the vaccine.
While Glaxo declined to comment on the matter, Sanofi assured that, for its part, it had initiated talks with several countries, including the United Kingdom.
There is still no vaccine that can end the pandemic, and yet governments around the world seek to secure doses in advance, especially after U.S keep all doses of the drug Remdesivir from Gilead.
The government of Boris Johnson He explained via email that he is interacting with a large number of companies to negotiate access to vaccines and that announcements will be made when the deals are completed.
- Both pharmaceutical companies plan to begin a study compressing the early and mid-stages of clinical trials in September.
- Sanofi said in June that it expects approval to be in the first half of 2021, earlier than previously expected.
- The French firm suffered a setback this month when its drug drug developed with Regeneron was ineffective in treating Covid-19 in trials in the United States.
Back in the EU to develop the vaccine
The UK, which is still mired in numerous negotiations with the European Union to reach a trade deal, is considering joining the 27th campaign to develop a vaccine.
Last Thursday, the first week of in-person meetings ended, a day earlier than planned, due to a lack of understanding between both parties.